Source comparison
MK-677 Studied Frailty Research: Trial Comparison
Virginia 2009 (community-dwelling frail elderly, n=65, mean age 78) 25mg daily oral, 12 months Lean body mass (DEXA), gait speed (4m walk) +1.1 kg vs −0.2 kg placebo (p<0.001) Gait speed +0.13 m/s vs −0.02 m/s placebo (p=0.006) 18% treatment, 8% placebo Periph
This comparison does not assign a generated winner or score.
- Virginia 2009 (community-dwelling frail elderly, n=65, mean age 78)
- 25mg daily oral, 12 months
- Lean body mass (DEXA), gait speed (4m walk)
- +1.1 kg vs −0.2 kg placebo (p<0.001)
- Gait speed +0.13 m/s vs −0.02 m/s placebo (p=0.006)
- 18% treatment, 8% placebo
- Peripheral oedema (38%), fasting glucose ↑8–12 mg/dL, carpal tunnel symptoms (12%)
- Hip Fracture Recovery 2011 (post-surgical elderly, n=62, mean age 74)
- 25mg daily oral, 24 weeks starting 2 weeks post-op
- Lean mass recovery, return to pre-fracture gait speed
- 78% pre-fracture mass regained vs 52% placebo (p=0.009)
- Pre-fracture gait speed at 16 weeks vs 24 weeks placebo (p=0.021)
- 22% treatment, 12% placebo
- Fluid retention requiring diuretic adjustment (28%), hand numbness (15%), HbA1c ↑0.3–0.5% in diabetics
- Professional Assessment
- 25mg evening dosing is the validated frailty protocol; lower doses ineffective in elderly populations. Monitor glucose, fluid status, and renal function monthly. Not suitable for NYHA III/IV heart failure or uncontrolled diabetes. Lean mass gains reverse 8–12 weeks post-discontinuation. Long-term use required for sustained benefit.